Grifols S.A. ADR Stock
Grifols S.A. ADR Stock
A very strong showing by Grifols S.A. ADR today, with an increase of €0.45 (6.620%) compared to yesterday's price.
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | 6.620% | -1.449% | -13.924% | -6.207% | -10.526% | 7.087% | -50.817% |
| Eledon Pharmaceuticals Inc. | -2.400% | 0.826% | 40.230% | -24.691% | 90.625% | 32.609% | -78.783% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 0.000% | 0.000% | 20.327% | 14.955% | 7.292% | -47.179% |
| SELLAS Life Sciences Group Inc | 0.800% | -8.777% | 35.770% | 340.464% | 53.968% | 233.461% | -52.033% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat